Genomics

Breakout Ventures Welcomes Five New Venture Partners

Retrieved on: 
Tuesday, March 26, 2024
Biotechnology, Health, Finance, Pharmaceutical, Professional Services, Other Science, Research, Medical Devices, Start-Up, Data Analytics, Genetics, Health Technology, Science, Clinical Trials, HTP, Genomics, University of Cambridge, Ashland Global, UCSF, Data science, Twist Bioscience, Walter, MIT, Synthetic biology, Cell biology, UC, University, Software, Doctor of Philosophy, Elemental Machines, University of Michigan, Marshall Scholarship, Pleasure, Silicon, Biochemistry, Investment, Therapy, Ilan, Drug development, Multimedia, Coco, University of California, Berkeley, Management

Breakout Ventures , the home for creative bioscience entrepreneurs, is pleased to welcome five new venture partners.

Key Points: 
  • Breakout Ventures , the home for creative bioscience entrepreneurs, is pleased to welcome five new venture partners.
  • Walter advises numerous portfolio companies of VC and PE firms, including as a board member for Checkerspot, a Breakout Ventures investment.
  • Breakout supports our portfolio companies with more than just capital, and we are excited to welcome this group of insightful leaders.
  • To learn more about Breakout Ventures, visit: https://www.breakout.vc/ .

Watchmaker Genomics Launches Watchmaker mRNA Library Prep Kits - Featuring a Rapid Workflow and Sensitive mRNA Detection

Retrieved on: 
Tuesday, March 26, 2024
Medical Supplies, Medical Devices, Health, Genetics, Other Health, Biotechnology, Watchmaker, Polaris, Genomics, RNA, DNA, Gene expression, Messenger, Small RNA, Vaccine

Watchmaker Genomics, a supplier of innovative products for molecular analysis, announced the launch of the Watchmaker mRNA Library Prep Kit – designed to streamline and accelerate mRNA library preparation, offering both speed and sensitivity to the genomics community.

Key Points: 
  • Watchmaker Genomics, a supplier of innovative products for molecular analysis, announced the launch of the Watchmaker mRNA Library Prep Kit – designed to streamline and accelerate mRNA library preparation, offering both speed and sensitivity to the genomics community.
  • The Watchmaker mRNA Library Prep Kit generates high-quality mRNA libraries in under 5 hours with fewer handling and purification steps.
  • Additionally, it delivers exceptionally sensitive and accurate gene expression data, enabling researchers to uncover valuable biological insights.
  • "We are thrilled to make this kit widely available," said Brian Kudlow, Chief Scientific Officer at Watchmaker.

Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer Center

Retrieved on: 
Monday, March 25, 2024
Science, Biotechnology, Research, Oncology, Health, Medical Devices, Health Technology, Genetics, PCR, Genomics, EVP, International, Biomarker, Cancer, Proteomics, MCRA, Bio-Rad Laboratories, MSRA, MSK

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung diseases, today announced that it has entered into a new master collaborative research agreement (MCRA) with Memorial Sloan Kettering Cancer Center (MSK) under which the teams will collaborate on a development plan for diagnostic tests aimed at improving the treatment of cancer.

Key Points: 
  • Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung diseases, today announced that it has entered into a new master collaborative research agreement (MCRA) with Memorial Sloan Kettering Cancer Center (MSK) under which the teams will collaborate on a development plan for diagnostic tests aimed at improving the treatment of cancer.
  • Biodesix will utilize its array of genomics, proteomics, and data mining capabilities with the aim of developing and commercializing oncology biomarker assays in collaboration with MSK .
  • “The expansion of our previous master sponsored research agreement (MSRA) into a master collaborative research agreement with MSK is a significant milestone for Biodesix and for biomarkers in oncology diagnostics.
  • Biodesix looks forward to co-developing and validating new test concepts under these agreements,” said Scott Hutton, CEO, Biodesix.

Verge Genomics and Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635

Retrieved on: 
Monday, March 25, 2024
Technology, Neurology, Genetics, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Artificial Intelligence, Survival, Verge, ALS, Caregiver, Social justice, Partnership, Patient, Tissue, News, Ferrer, POC, Neuron, B Corporation (certification), Clinical trial, Genomics, DSM-IV codes, Drug development, Safety, Pharmaceutical industry

VRG50635 is a potential best-in-class, small molecule inhibitor of PIKfyve, a therapeutic target for ALS discovered in diseased human tissues using CONVERGE®, Verge’s all-in-human, AI-powered platform.

Key Points: 
  • VRG50635 is a potential best-in-class, small molecule inhibitor of PIKfyve, a therapeutic target for ALS discovered in diseased human tissues using CONVERGE®, Verge’s all-in-human, AI-powered platform.
  • Under the terms of the agreement, Ferrer will obtain the exclusive rights to co-develop and commercialize VRG50635 for ALS in multiple regions outside of the United States of America.
  • Verge has retained all rights to development and commercialization for VRG50635 for all uses in the United States and all countries outside the agreement.
  • “We're thrilled to work with Ferrer to progress VRG50635 through clinical development and towards potential commercialization.

Nucleus Genomics launches to bring whole-genome sequencing to the public

Retrieved on: 
Monday, March 25, 2024
Technology, Research, Medical Devices, Genetics, Biotechnology, Health, Pharmaceutical, Science, Consumer Electronics, Human Genome Project, WGS, Blood pressure, Genomics, Certification, Informatics, Genetic testing, Nucleus, Risk, Human, PRS, DNA, Accreditation, Breast, CAP, Overalls, Facial muscles, Cancer, CLIA, Breast cancer, BRCA2, BMI, BRCA1, Vaccine

Nucleus Genomics , the next-generation genetic testing and analysis company, today announced the launch of its DNA analysis product to bring the benefits of personalized medicine to everyone.

Key Points: 
  • Nucleus Genomics , the next-generation genetic testing and analysis company, today announced the launch of its DNA analysis product to bring the benefits of personalized medicine to everyone.
  • Nucleus will also offer pre-orders for its premium clinical-grade whole-genome sequencing (WGS) service, in which a customer’s entire set of DNA will be read and analyzed.
  • Nucleus is proud to sequence all customer samples in the U.S. on Illumina’s NovaSeq X Plus, the sequencing company’s newest and most innovative high-throughput sequencing instrument.
  • Working with Illumina, Nucleus is leveraging this latest sequencing technology to make WGS broadly accessible to power personalized healthcare.

Smart/Artificial Intelligence for In-Vitro Diagnostics Market Research Report 2024 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 21, 2024
General Health, Oncology, Consumer, Technology, Medical Devices, Hospitals, Genetics, Artificial Intelligence, Health Technology, Baby, Maternity, Biotechnology, Practice Management, Health, Diagnosis, Genomics, Growth, Infection, Medication, Science, Application, Intelligence, Consultant, Artificial intelligence, Research, Hospital, AI, Laboratory, Radiology, Physician, Medicine, Medical device

The "Smart In-Vitro Diagnostics - Artificial Intelligence for In Vitro Diagnostics Markets by Application, by Technology and by User with Executive and Consultant Guides 2023-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Smart In-Vitro Diagnostics - Artificial Intelligence for In Vitro Diagnostics Markets by Application, by Technology and by User with Executive and Consultant Guides 2023-2027" report has been added to ResearchAndMarkets.com's offering.
  • The market is exploding as physicians use all the information they can get to battle disease.
  • Broad-spectrum blood testing and artificial intelligence will routinely provide medical diagnosis in the near future according to a this new report.
  • The report explores recent developments in artificial intelligence, genomics, and costs that affect the market outlook.

Quantum-Si Appoints Former Illumina and Cisco Systems Executive, Paula Dowdy, to its Board of Directors

Retrieved on: 
Thursday, March 21, 2024
Biotechnology, Technology, Health, General Health, Pharmaceutical, Oncology, Semiconductor, Other Science, Research, Science, Hardware, Genomics, Growth, SVP, University, Software, Cisco, Proteomics, MBA, Pepperdine University, Protein sequencing, Multimedia, Management

Prior to Illumina, Ms. Dowdy spent over 20 years at Cisco Systems, Inc., and held various positions in products, services, and software in the United States, and globally.

Key Points: 
  • Prior to Illumina, Ms. Dowdy spent over 20 years at Cisco Systems, Inc., and held various positions in products, services, and software in the United States, and globally.
  • “We are thrilled to welcome Paula to our Board of Directors,” said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si.
  • “I am honored to join the Quantum-Si Board of Directors during this pivotal moment in the Company’s journey,” said Ms. Dowdy.
  • Her appointment to the Quantum-Si Board of Directors is effective as of today.

Cue Health Announces Strategic Actions to Position Company for Next Stage

Retrieved on: 
Wednesday, March 20, 2024
Health, Pharmaceutical, Health Technology, Telemedicine, Virtual Medicine, Medical Supplies, Genomics, Medicine, Roche, Khattak, Vaccine, Management

Cue Health Inc. ("Cue" or the “Company”) (Nasdaq: HLTH), a healthcare technology company, today announced strategic actions implemented by its Board of Directors (the “Board”) to best position the Company for its next stage:

Key Points: 
  • Cue Health Inc. ("Cue" or the “Company”) (Nasdaq: HLTH), a healthcare technology company, today announced strategic actions implemented by its Board of Directors (the “Board”) to best position the Company for its next stage:
    Clint Sever, co-founder and current Chief Product Officer, has been appointed CEO, effective immediately.
  • “Cue has an outstanding executive team and we are confident that Clint can seamlessly assume the CEO role, given his deep experience, expertise and familiarity with Cue.
  • We are also pleased to have Paul and Lisa join Cue as strategic advisors, whose experience and insights will be critical to Cue’s next phase.
  • This vision continues to inspire and drive the important work we do every day,” said Clint Sever, CEO of Cue.

Agendia Announces New Data from I-SPY 2 Showcasing Ability of New Signature ImPrintTN to Predict Immunotherapy Response in Patients with Triple Negative Breast Cancer

Retrieved on: 
Wednesday, March 20, 2024
Biotechnology, FDA, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Genetics, Science, Clinical Trials, IO, Conference, Entrepreneurship, Response, Immunotherapy, Partnership, Risk, Patient, MammaPrint, University, Biology, University of California, Imprint, Genomics, Breast cancer, Medical laboratory, RPS, Pharmaceutical industry

Agendia®, Inc. today announced new data from the I-SPY 2 trial showcasing its ImPrint signature for patients with triple negative (TN) breast cancer, shared by I-SPY 2 researchers in an oral presentation at the 14th European Breast Cancer Conference in Milan, Italy.

Key Points: 
  • Agendia®, Inc. today announced new data from the I-SPY 2 trial showcasing its ImPrint signature for patients with triple negative (TN) breast cancer, shared by I-SPY 2 researchers in an oral presentation at the 14th European Breast Cancer Conference in Milan, Italy.
  • Agendia has been in partnership with Quantum Leap Healthcare Collaborative, the sponsors of the neoadjuvant biomarker-rich I-SPY 2 trial, since 2010.
  • ), investigates the utility of a refined version of ImPrint, called ImPrintTN, designed to provide more accurate predictions to response to common immunotherapy (IO) regimens for TN patients.
  • “Many immunotherapy treatments can have difficult, severe adverse side effects on patients that can outweigh the benefit of the treatment.

DNAnexus Adds NVIDIA NIM and CUDA-X Microservices to Precision Health Data Cloud to Accelerate Drug Discovery and Improve Patient Care

Retrieved on: 
Tuesday, March 19, 2024
Technology, Health Technology, Software, Networks, Other Health, Internet, Health, General Health, Data Management, Cloud, Genomics, Drug discovery, AI, Biology, Chemistry, Ecosystem, API, CPU, Privacy, NVIDIA, Cryptocurrency

DNAnexus, Inc. , the provider of the Precision Health Data Cloud, today announced that it is integrating new NVIDIA NIM and CUDA-X microservices.

Key Points: 
  • DNAnexus, Inc. , the provider of the Precision Health Data Cloud, today announced that it is integrating new NVIDIA NIM and CUDA-X microservices.
  • These microservices are designed to allow researchers and bioinformaticians to easily integrate NVIDIA Parabricks tools into new and existing genomics workflows using the DNAnexus Precision Health Data Cloud to accelerate drug discovery and improve patient care.
  • The NVIDIA Parabricks microservices address the computational bottlenecks in genomics analysis, providing accelerated alignment and variant calling workflows.
  • These production-grade microservices can be deployed through the NVIDIA AI Enterprise 5.0 software platform, now available directly through DNAnexus.